TOKYO, Apr 01 (Pulse News Wire) – Solasia Pharma K.K. (4597.T) announced today that it will exercise additional subscription rights in Isofol Medical AB, its development partner for SP-05.
As part of this investment, Solasia will subscribe to 2,083,332 new shares at a price of 0.48 SEK per share. Following this transaction, Solasia's holding in Isofol will increase to 8,333,328 shares, representing 2.6% of Isofol’s equity. This additional investment is expected to fund SP-05 development activities, providing direct support to the compound's progress.
It also aims to strengthen future collaboration with Isofol and enable Solasia to benefit from economic value generated outside Japan through SP-05 advancements. The impact of this investment on Solasia's performance is anticipated to be positive in the long term but is not expected to affect the fiscal year 2026 consolidated results. Note: Forward-looking statements in this press release are based on current available information and reasonable assumptions.
Actual outcomes could differ due to various factors such as economic conditions, exchange rate fluctuations, and competitive situations.
🟢 Confidence: High AI-translated content.